S'identifier

Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.

For instance, acrolein, a metabolic byproduct of cyclophosphamide, binds to renal tissues and accumulates within renal cells, causing nephrotoxic effects. Lipophilic drugs, on the other hand, tend to bind to body fat. Since fat is a poorly perfused tissue, it functions as a stable drug reservoir for these drugs. Additionally, bones can act as drug storage sites, as seen in the treatment of osteoporosis using alendronate therapy. In this case, the phosphonate binds to hydroxyapatite crystals in the mineralized bone matrix, resisting degradation and preserving the bone structure. Moreover, bones can serve as reservoirs for toxic metals, which may be released slowly into the bloodstream, leading to various adverse effects.

Tags
Drug DistributionTissue BindingSystemic CirculationInterstitial FluidIntracellular FluidDrug AccumulationLocal ToxicityAcroleinCyclophosphamideNephrotoxic EffectsLipophilic DrugsBody FatDrug ReservoirsBonesAlendronate TherapyHydroxyapatite Crystals

Du chapitre 3:

article

Now Playing

3.10 : Drug Distribution: Tissue Binding

Pharmacokinetics

2.3K Vues

article

3.1 : Pharmacocinétique : Vue d’ensemble

Pharmacokinetics

4.6K Vues

article

3.2 : Mécanisme d’absorption du médicament : transport membranaire passif

Pharmacokinetics

3.2K Vues

article

3.3 : Mécanisme d’absorption du médicament : transport membranaire médié par le transporteur

Pharmacokinetics

3.1K Vues

article

3.4 : Absorption des médicaments : facteurs affectant l’absorption gastro-intestinale

Pharmacokinetics

3.4K Vues

article

3.5 : Biodisponibilité : Vue d’ensemble

Pharmacokinetics

2.3K Vues

article

3.6 : Facteurs influençant la biodisponibilité : élimination au premier passage

Pharmacokinetics

5.7K Vues

article

3.7 : Bioéquivalence : Vue d’ensemble

Pharmacokinetics

842 Vues

article

3.8 : Effet de premier passage

Pharmacokinetics

4.7K Vues

article

3.9 : Évolution temporelle de l’effet du médicament

Pharmacokinetics

1.8K Vues

article

3.11 : Barrières physiologiques

Pharmacokinetics

3.1K Vues

article

3.12 : Distribution du médicament : liaison aux protéines plasmatiques

Pharmacokinetics

3.8K Vues

article

3.13 : Modèles à compartiments : Modèle à compartiment unique

Pharmacokinetics

1.9K Vues

article

3.14 : Modèles à compartiments : Modèle à deux compartiments

Pharmacokinetics

4.8K Vues

article

3.15 : Distribution des médicaments : Volume de distribution

Pharmacokinetics

3.5K Vues

See More

JoVE Logo

Confidentialité

Conditions d'utilisation

Politiques

Recherche

Enseignement

À PROPOS DE JoVE

Copyright © 2025 MyJoVE Corporation. Tous droits réservés.